Iclusig15 - GR (Ponatinib Tablet) 15mg

Iclusig 15mg tablets contain ponatinib, a kinase inhibitor prescribed for certain blood cancers. This oral treatment targets specific pathways to help manage disease progression. Suitable for patients requiring targeted therapy. Short-term and long-term use may vary by condition.

Strength

15mg

Manufacturer / TM Owner

Incyte Biosciences Distribution B.V

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ponatinib 15mg tablets are used to treat specific types of leukemia, including chronic myeloid leukemia and acute lymphoblastic leukemia. It is prescribed when other treatments have not been effective or when certain genetic mutations are present. Patients often use this medication to help control disease progression and manage symptoms.

Side Effects

Common effects may include fatigue, headache, or digestive discomfort. Some users report mild nausea or skin reactions. These effects are typically temporary and vary by individual. Regular monitoring is advised to assess tolerance and response.

Precautions & Warnings

Store ponatinib tablets at room temperature away from moisture and heat. Keep out of reach of children and pets. Avoid crushing or splitting tablets unless directed. Inform your healthcare provider about all medications and supplements you are taking before starting treatment.

Avoid Interactions

Ponatinib may interact with other drugs, including certain antibiotics, antifungals, and heart medications. Grapefruit products can affect how the body processes ponatinib. Alcohol use should be discussed with a healthcare provider due to potential interactions.

Frequently Asked Questions

Ponatinib 15mg tablets are used to treat certain types of leukemia, including chronic myeloid leukemia and acute lymphoblastic leukemia.

Take ponatinib exactly as prescribed by your doctor, usually once daily with or without food.

Common side effects may include fatigue, headache, nausea, or skin reactions.

Grapefruit products may interact with ponatinib; consult your healthcare provider before consuming them.

Ponatinib may cause harm to an unborn baby; discuss risks and contraception with your doctor before use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.